Tuberculosis prevention: Cost-effectiveness analysis of isoniazid chemoprophylaxis

D. N. Rose, Clyde B. Schechter, M. C. Fahs, A. L. Silver

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Isoniazid chemoprophylaxis is not recommended for all persons infected with tubercle bacilli. Becuase of the small but significant risk of isoniazid hepatotoxicity, chemoprophylaxis is reserved for only those at the highest risk of tuberculosis activation. To evaluate this policy, we performed a cost-effectiveness analysis of isoniazid chemoprophylaxis for two populations with positive tuberculin skin tests: recent tuberculin converters, who are at high risk for activation, and older tuberculin reactors, who have a low risk for activation and for whom chemoprophylaxis is not now recommended. The cost-effectiveness ratios found were stable, despite wide variations in model assumptions and probability estimates. For high-risk tuberculin reactors, chemoprophylaxis resulted in net medical care monetary savings, extended life expectancy, and fewer fatal illnesses. For low-risk tuberculin reactors, chemoprophylaxis resulted in positive, but small, health effects. Because the cost to gain these positive effects were also small, the resulting cost-effectiveness ratios were reasonable and in the realm of accepted prevention strategies: $12,625 to gain one year of life and $35,011 to avert one death. These findings suggest that the current policy is too restrictive and that many in the large population of low-risk tuberculin reactors should be considered for isoniazid chemoprophylaxis.

Original languageEnglish (US)
Pages (from-to)102-109
Number of pages8
JournalAmerican Journal of Preventive Medicine
Volume4
Issue number2
StatePublished - 1988
Externally publishedYes

Fingerprint

Isoniazid
Chemoprevention
Cost-Benefit Analysis
Tuberculosis
Tuberculin
Tuberculin Test
Life Expectancy
Skin Tests
Bacillus
Population
Costs and Cost Analysis
Health

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health

Cite this

Tuberculosis prevention : Cost-effectiveness analysis of isoniazid chemoprophylaxis. / Rose, D. N.; Schechter, Clyde B.; Fahs, M. C.; Silver, A. L.

In: American Journal of Preventive Medicine, Vol. 4, No. 2, 1988, p. 102-109.

Research output: Contribution to journalArticle

@article{ff2b10323f8a46a6a3b128b9bebcb226,
title = "Tuberculosis prevention: Cost-effectiveness analysis of isoniazid chemoprophylaxis",
abstract = "Isoniazid chemoprophylaxis is not recommended for all persons infected with tubercle bacilli. Becuase of the small but significant risk of isoniazid hepatotoxicity, chemoprophylaxis is reserved for only those at the highest risk of tuberculosis activation. To evaluate this policy, we performed a cost-effectiveness analysis of isoniazid chemoprophylaxis for two populations with positive tuberculin skin tests: recent tuberculin converters, who are at high risk for activation, and older tuberculin reactors, who have a low risk for activation and for whom chemoprophylaxis is not now recommended. The cost-effectiveness ratios found were stable, despite wide variations in model assumptions and probability estimates. For high-risk tuberculin reactors, chemoprophylaxis resulted in net medical care monetary savings, extended life expectancy, and fewer fatal illnesses. For low-risk tuberculin reactors, chemoprophylaxis resulted in positive, but small, health effects. Because the cost to gain these positive effects were also small, the resulting cost-effectiveness ratios were reasonable and in the realm of accepted prevention strategies: $12,625 to gain one year of life and $35,011 to avert one death. These findings suggest that the current policy is too restrictive and that many in the large population of low-risk tuberculin reactors should be considered for isoniazid chemoprophylaxis.",
author = "Rose, {D. N.} and Schechter, {Clyde B.} and Fahs, {M. C.} and Silver, {A. L.}",
year = "1988",
language = "English (US)",
volume = "4",
pages = "102--109",
journal = "American Journal of Preventive Medicine",
issn = "0749-3797",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Tuberculosis prevention

T2 - Cost-effectiveness analysis of isoniazid chemoprophylaxis

AU - Rose, D. N.

AU - Schechter, Clyde B.

AU - Fahs, M. C.

AU - Silver, A. L.

PY - 1988

Y1 - 1988

N2 - Isoniazid chemoprophylaxis is not recommended for all persons infected with tubercle bacilli. Becuase of the small but significant risk of isoniazid hepatotoxicity, chemoprophylaxis is reserved for only those at the highest risk of tuberculosis activation. To evaluate this policy, we performed a cost-effectiveness analysis of isoniazid chemoprophylaxis for two populations with positive tuberculin skin tests: recent tuberculin converters, who are at high risk for activation, and older tuberculin reactors, who have a low risk for activation and for whom chemoprophylaxis is not now recommended. The cost-effectiveness ratios found were stable, despite wide variations in model assumptions and probability estimates. For high-risk tuberculin reactors, chemoprophylaxis resulted in net medical care monetary savings, extended life expectancy, and fewer fatal illnesses. For low-risk tuberculin reactors, chemoprophylaxis resulted in positive, but small, health effects. Because the cost to gain these positive effects were also small, the resulting cost-effectiveness ratios were reasonable and in the realm of accepted prevention strategies: $12,625 to gain one year of life and $35,011 to avert one death. These findings suggest that the current policy is too restrictive and that many in the large population of low-risk tuberculin reactors should be considered for isoniazid chemoprophylaxis.

AB - Isoniazid chemoprophylaxis is not recommended for all persons infected with tubercle bacilli. Becuase of the small but significant risk of isoniazid hepatotoxicity, chemoprophylaxis is reserved for only those at the highest risk of tuberculosis activation. To evaluate this policy, we performed a cost-effectiveness analysis of isoniazid chemoprophylaxis for two populations with positive tuberculin skin tests: recent tuberculin converters, who are at high risk for activation, and older tuberculin reactors, who have a low risk for activation and for whom chemoprophylaxis is not now recommended. The cost-effectiveness ratios found were stable, despite wide variations in model assumptions and probability estimates. For high-risk tuberculin reactors, chemoprophylaxis resulted in net medical care monetary savings, extended life expectancy, and fewer fatal illnesses. For low-risk tuberculin reactors, chemoprophylaxis resulted in positive, but small, health effects. Because the cost to gain these positive effects were also small, the resulting cost-effectiveness ratios were reasonable and in the realm of accepted prevention strategies: $12,625 to gain one year of life and $35,011 to avert one death. These findings suggest that the current policy is too restrictive and that many in the large population of low-risk tuberculin reactors should be considered for isoniazid chemoprophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=0023910248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023910248&partnerID=8YFLogxK

M3 - Article

C2 - 3134928

AN - SCOPUS:0023910248

VL - 4

SP - 102

EP - 109

JO - American Journal of Preventive Medicine

JF - American Journal of Preventive Medicine

SN - 0749-3797

IS - 2

ER -